1. Market Research
  2. > All Companies
  3. > Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile

Summary

Cerus Corporation (Cerus) is a biomedical products manufacturing company. It undertakes the development and commercialization of novel, proprietary products and technologies, intended to make the blood supply safer. The company focuses on the development and commercialization of its flagship Intercept Blood System based on its proprietary Helinx technology. Cerus has the worldwide rights of Intercept for three blood components, namely, platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion. It markets its product in the US, Europe, Russia, the Middle East and selected countries of other regions of the world for the treatment of both platelets and plasma for transfusions and it is also being developed for the treatment of red blood cells. Cerus is headquartered in Concord, California, the US.

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cerus Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 6
Cerus Corporation, Medical Equipment Deals By Type, 2009 to YTD 2015 7
Cerus Corporation, Medical Equipment, Deals By Region, 2009 to YTD 2015 8
Cerus Corporation, Medical Equipment, Deals By Market, 2009 to YTD 2015 9
Cerus Corporation, Medical Equipment, Deals Summary, 2009 to YTD 2015 10
Cerus Corporation, Medical Equipment, Deal Details 11
Partnerships 11
Cerus Terminates Licensing Agreement With BioOne 11
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 12
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 13
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 14
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 18
Cerus Enters Into Agreement With CSL 19
Cerus Enters Into An Agreement With Grifols 20
Equity Offering 21
Cerus Prices Public Offering of Shares for USD70 Million 21
Cerus Completes Public Offering Of Shares For US$40.3 Million 23
Cerus Completes Underwritten Public Offering Of US$21 Million 25
Cerus Completes Private Placement Of Units For US$13.2 Million 27
Cerus Corporation - Key Competitors 29
Key Employees 30
Locations And Subsidiaries 31
Head Office 31
Other Locations and Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
May 29, 2014: Cerus Signs Five-Year Agreement With Belgian Red Cross Flanders for the INTERCEPT Blood System for Platelets 32
Financial Announcements 33
Aug 06, 2015: Cerus Reports Second Quarter 2015 Results 33
May 05, 2015: Cerus Reports First Quarter 2015 Results 35
Feb 26, 2015: Cerus Reports Fourth Quarter and Year-End 2014 Results 37
Nov 04, 2014: Cerus Reports Third Quarter 2014 Results 39
Jul 31, 2014: Cerus Reports Second Quarter 2014 Results 41
Jul 31, 2014: Cerus Corporation Reports Second Quarter 2014 Results 43
May 01, 2014: Cerus Reports First Quarter 2014 Results 45
Feb 25, 2014: Cerus Reports Fourth Quarter and Year-End 2013 Results 47
Corporate Communications 49
Jun 08, 2015: Richard J. Benjamin, MD PhD Appointed as Cerus Corporation's New Chief Medical Officer 49
Mar 25, 2014: Frank Witney Joins Cerus Board of Directors 50
Product News 51
Apr 27, 2015: Cerus To Present At AABB Symposium On Pathogen-Reduced Components 51
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets 52
Feb 27, 2015: Cerus Signs INTERCEPT Platelet Agreement With Sweden's Largest Blood Product Supplier 53
Jan 28, 2015: Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System 54
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 55
Dec 22, 2014: Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 56
Dec 18, 2014: FDA Approves INTERCEPT Blood System for Platelets 57
Dec 16, 2014: Cerus Secures FDA Approval For Intercept Blood Plasma System 59
Sep 10, 2014: Cerus Submits IDE Supplement to Make INTERCEPT Platelets Available Pre-Approval in U.S. Areas at Risk from Outbreaks of Chikungunya and Dengue 60
Product Approvals 61
Dec 18, 2014: FDA Approves INTERCEPT Blood System for Platelets 61
Dec 16, 2014: Cerus Secures FDA Approval For Intercept Blood Plasma System 63
Clinical Trials 64
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets 64
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 65
Dec 22, 2014: Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 66
Other Significant Developments 67
Jul 13, 2015: Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Cerus Corporation, Medical Equipment, Key Facts, 2014 1
Cerus Corporation, Medical Equipment, Deals Summary, 2009 to YTD 2015 1
Cerus Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 6
Cerus Corporation, Medical Equipment Deals By Type, 2009 to YTD 2015 7
Cerus Corporation, Medical Equipment, Deals By Region, 2009 to YTD 2015 8
Cerus Corporation, Deals By Market, 2009 to YTD 2015 9
Cerus Corporation, Medical Equipment, Deals Summary, 2009 to YTD 2015 10
Cerus Terminates Licensing Agreement With BioOne 11
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 12
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 13
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 14
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 18
Cerus Enters Into Agreement With CSL 19
Cerus Enters Into An Agreement With Grifols 20
Cerus Prices Public Offering of Shares for USD70 Million 21
Cerus Completes Public Offering Of Shares For US$40.3 Million 23
Cerus Completes Underwritten Public Offering Of US$21 Million 25
Cerus Completes Private Placement Of Units For US$13.2 Million 27
Cerus Corporation, Key Competitors 29
Cerus Corporation, Key Employees 30
Cerus Corporation, Subsidiaries 31

List of Figures
Cerus Corporation, Medical Equipment, Deals by Type, 2009 to YTD 2015 1
Cerus Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 1
Cerus Corporation, Medical Equipment, Deals By Region, 2009 to YTD 2015 1
Cerus Corporation, Medical Equipment, Deals By Market, 2009 to YTD 2015 1
Cerus Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 6
Cerus Corporation, Medical Equipment, Deals by Type, 2009 to YTD 2015 7
Cerus Corporation, Medical Equipment, Deals By Region, 2009 to YTD 2015 8
Cerus Corporation, Medical Equipment, Deals by Market, 2009 to YTD 2015 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Immunetics, Inc. - Product Pipeline Analysis, 2015 Update

Immunetics, Inc. - Product Pipeline Analysis, 2015 Update

  • $ 750
  • Company report
  • December 2015
  • by Global Data

Summary Immunetics, Inc. (Immunetics) is a diagnostic company that research and develops assay technology for blood screening and infectious disease diagnosis. The company’s products include diagnostic ...

Micronics, Inc. (of Sony Group) - Product Pipeline Analysis, 2015 Update

Micronics, Inc. (of Sony Group) - Product Pipeline Analysis, 2015 Update

  • $ 750
  • Company report
  • October 2015
  • by Global Data

Summary Micronics, Inc. (Micronics), a subsidiary of Sony Corporation of America is a medical device company that develops and markets in vitro diagnostic products for disease diagnosis, prognosis and ...

Immucor, Inc. - Product Pipeline Analysis, 2015 Update

Immucor, Inc. - Product Pipeline Analysis, 2015 Update

  • $ 750
  • Company report
  • November 2015
  • by Global Data

Summary Immucor, Inc. (Immucor) is a global in-vitro diagnostics company, which specializes in the area of pre-transfusion diagnostics. It carries out the development, production and sale of a comprehensive ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.